Hemogenyx Pharmaceuticals annual free cash flow
2020
2021
2022
2023
2024
2025
Hemogenyx Pharmaceuticals Free Cash Flow (FCF) History (HEMO)
Hemogenyx Pharmaceuticals reported −£3.5M in free cash flow for fiscal 2025, an increase of £701,431 from the previous fiscal year.
View full Hemogenyx Pharmaceuticals company overviewHemogenyx Pharmaceuticals free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −£3.5M | £701,431 | — | — |
| 2024 | 2024-12-31 | −£4.2M | £2.1M | — | — |
| 2023 | 2023-12-31 | −£6.2M | −£2.9M | — | — |
| 2022 | 2022-12-31 | −£3.3M | −£75,996 | — | — |
| 2021 | 2021-12-31 | −£3.3M | −£1.3M | — | — |
| 2020 | 2020-12-31 | −£2.0M | — | — | — |
Hemogenyx Pharmaceuticals free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −£2.0M to −£3.5M, a net decrease of £1.5M.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Hemogenyx Pharmaceuticals source filings ↗